OCA is a first-in-class selective farnesoid X receptor (FXR) agonist that possesses anti-cholestatic and hepatoprotective effects [46] and is approved as Ocaliva for the treatment of primary biliary cholangitis [47]. This evidence concerns the gene NR1H4 and biliary liver cirrhosis.